Laboratory Proficiency Testing Market

The global laboratory proficiency testing market is projected to reach USD 1.6  billion by 2028 from USD 1.2  billion in 2023, at a CAGR of 7.4%. As proficiency testing is obligatory for laboratories operating in various industries subject to regulation by organizations like CLIA, CLSI, and APLAC, the proficiency testing market is poised for substantial growth in the forecast period. It serves as a fundamental prerequisite for achieving operational excellence and accreditation across multiple sectors, contributing significantly to the global expansion of the laboratory proficiency testing market. Also, the increasing number of laboratory accreditations, stringent safety and quality regulations for increasing focus on water testing, and food and pharmaceutical products are the other major factors driving market growth. However, the need for substantial capital investment to facilitate precise and highly sensitive testing is anticipated to act as a restraining factor for the growth of this market in the projected period.

The prominent players in the laboratory proficiency testing market are LGC Limited (UK), College of American Pathologists (US), Bio-Rad Laboratories (US), Merck KGaA (Germany), American Proficiency Institute (US), Randox Laboratories (UK), Fapas (Fera Science Ltd.) (UK), Waters Corporation (US), QACS (Greece), Weqas (UK), AOAC INTERNATIONAL (US), Bipea (France), SPEX CertiPrep (US), Absolute Standards Inc. (US), Trilogy Analytical Laboratory (US), Advanced Analytical Solutions (US), American Industrial Hygiene Association (US), Matrix Sciences (US), Aashvi Proficiency Testing & Analytical Services (India), Global Proficiency (New Zealand), The Emerald Test (US), FLUXANA GmbH & Co. KG (Germany), Phenova Inc. (US), FARE Labs (India), Go Plus Services SDN BHD (Malaysia), and Muva Kempten GmbH (Germany).

To know about the assumptions considered for the study download the pdf brochure

LGC Limited (UK) holds the leading position in the laboratory proficiency testing market and offers a wide range of proficiency testing solutions through its flagship brand, AXIO. The company extends its proficiency testing schemes globally, serving 13,000 laboratories in over 160 countries facilitating approximately 2,000 proficiency tests each year. The company primarily employs organic growth strategies, such as introducing new products, to maintain and enhance its market share. For instance, in April 2020, the company launched a proficiency testing (PT) service for the detection of SARS-CoV-2 (COVID-19) by nucleic acid amplification testing. In addition, in July 2022, the company introduced a free app-based training program for cannabis testing laboratories, aiming to assist their educational endeavors.  Also, in July 2023, the company acquired Kova International, Inc. to strengthen its portfolio of quality measurement tools.

 College of American Pathologists (CAP) holds the second position in the laboratory proficiency testing market. In 2020, CAP witnessed the participation of over 25,000 laboratories in proficiency testing (PT) programs and granted accreditation to more than 5,000 laboratories worldwide. Their PT programs are widely adopted, with over 25,000 laboratories across the world utilizing them. The company is committed to strengthening its portfolio of PT services in the proficiency testing market, by utilizing a combination of organic and inorganic growth strategies. These strategies encompass activities like launching new products and making strategic investments. For instance, in March 2023, the company launched a new proficiency testing (PT) program focused on the monkeypox (mpox) virus. Introducing the new mpox PT program, will help several laboratories in enhancing the quality assurance of their molecular testing processes.

Bio-Rad Laboratories is one of the leading positions in the proficiency testing market. The company has a comprehensive product portfolio, encompassing more than 3,000 clinical diagnostic tests and products, catering to both the Life Science and Clinical Diagnostic segments. The company is recognized for its fully accredited PT/EQA programs, covering chemistry (serum and urine), immunoassay, therapeutic drugs, and hematology. In 2022,  the clinical diagnostics segment observed a decrease of 4.3% in sales in 2022 as compared to 2021. Although there were a few fluctuations in demand, the overall sales were largely unaffected. With its strong geographic presence and wide distribution network, Bio-Rad Laboratories has established itself as a leader in the global market.

Related Reports:

Laboratory Proficiency Testing Market by Industry (Clinical Diagnostics, Microbiology, Pharmaceutical, Food & Animal Feed, Water, Opioid), Technology (PCR, Cell Culture), and Region; Unmet Needs, Stakeholder & Buying Criteria - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]